A Phase 2, Open-label Evaluation of CRS-207 and Pembrolizumab in Adults With Recurrent or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinomas
Phase of Trial: Phase II
Latest Information Update: 12 Aug 2017
At a glance
- Drugs CRS 207 (Primary) ; Pembrolizumab (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Aduro BioTech
- 08 May 2017 Status changed from not yet recruiting to recruiting.
- 02 May 2017 According to an Aduro BioTech media release, the company plans to initiate this trial in the first half of 2017.
- 24 Apr 2017 New trial record